Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Introduction
00:00 • 2min
The Conflicts of Interest in Pathogen and Activation
02:09 • 3min
The Pathogen and Activation of Blood Banking
04:49 • 3min
The Limitations of Pathogen Activation in Blood Banking
07:43 • 5min
The Big Push for Testing for Zika
12:18 • 3min
The Importance of Public Visibility in Blood Banking
14:56 • 3min
The Drawbacks and Potential Issues With Bacterial Contamination Testing
17:26 • 2min
The Different Approach to Pathogen Inactivation
19:20 • 2min
The Differences Between Cirrus and Mirasol
21:26 • 2min
The Differences Between the Mirasol and the Intercept Systems
23:08 • 4min
The Toxicity of Platelet Transfusions
26:46 • 2min
The Effect of Platelet Transfusions on Bleeding
29:06 • 2min
The Problem With Platelet Yields in the Blood Donor Center Industry
31:05 • 2min
The Concern Is More Triples Becoming Doubles Than Doubles Becoming Singles
33:13 • 2min
The Cost of Pathogen and Activation in Transfusion Medicine
34:44 • 5min
The FDA's Guidance on Syphilis Testing
39:34 • 5min
The Future of Plasma
44:33 • 4min
Serous's S303 Technology Is in Clinical Trial
48:14 • 3min
The Progress of the Mirasol Packed Cell Clinical Trial
51:14 • 2min
The Future of Bloodborne Infectious Diseases
53:11 • 5min
The Effects of Myrosol Whole Blood on Malaria Infection
58:02 • 1min
The Difference Between Pathogen Inactivation and Pathogen Reduction
59:29 • 3min
The Future of Pathogen Reduction
01:02:05 • 3min